Literature DB >> 14633630

Humanized knock-in mice expressing chimeric prion protein showed varied susceptibility to different human prions.

Yuzuru Taguchi1, Shirou Mohri, James W Ironside, Tamaki Muramoto, Tetsuyuki Kitamoto.   

Abstract

Mice to which human prions efficiently transmit in short incubation periods are valuable not only as research tools of human prions but also as reliable diagnostic tools. We recently produced a line of knock-in mouse expressing a unique human-mouse chimeric PrP (Ki-ChM mouse), which has mouse-specific residues practically only at the C-terminal part after posttranslational modification, and here we attempted transmission of various human prions to assess the susceptibility profile of the mouse. Susceptibility varied considerably depending on prions inoculated: highly susceptible to MM1 and MV1 types of sporadic Creutzfeldt-Jakob disease (CJD), developing disease within approximately 150 days, familial CJD with M232R mutation, and dura graft-associated CJD (dCJD) without amyloid plaque; less susceptible to MM2-type sporadic CJD and variant CJD, with some mice lacking any sign of transmission; and totally resistant to VV2 type sporadic CJD and dCJD with amyloid plaque. The rather short incubation time achieved by Ki-ChM mice suggests new approaches to produce mice that develop prion disease with very short incubation periods. We compared the characteristic susceptibility profile of Ki-ChM with those of other precedent transgenic mice and discussed, including the prospects in developing genetically engineered mice susceptible to human prions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633630      PMCID: PMC1892390          DOI: 10.1016/S0002-9440(10)63613-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins.

Authors:  R J Kascsak; R Rubenstein; P A Merz; M Tonna-DeMasi; R Fersko; R I Carp; H M Wisniewski; H Diringer
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Organ distribution of proteinase-resistant prion protein in humans and mice with Creutzfeldt-Jakob disease.

Authors:  T Kitamoto; S Mohri; J Tateishi
Journal:  J Gen Virol       Date:  1989-12       Impact factor: 3.891

3.  Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene.

Authors:  Carsten Korth; Kiyotoshi Kaneko; Darlene Groth; Norbert Heye; Glenn Telling; James Mastrianni; Piero Parchi; Pierluigi Gambetti; Robert Will; James Ironside; Cornelia Heinrich; Patrick Tremblay; Stephen J DeArmond; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

Review 4.  Pathology of variant Creutzfeldt-Jakob disease.

Authors:  J W Ironside
Journal:  Arch Virol Suppl       Date:  2000

5.  Genetic influence on the structural variations of the abnormal prion protein.

Authors:  P Parchi; W Zou; W Wang; P Brown; S Capellari; B Ghetti; N Kopp; W J Schulz-Schaeffer; H A Kretzschmar; M W Head; J W Ironside; P Gambetti; S G Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

6.  Species-barrier-independent prion replication in apparently resistant species.

Authors:  A F Hill; S Joiner; J Linehan; M Desbruslais; P L Lantos; J Collinge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

7.  Follicular dendritic cell of the knock-in mouse provides a new bioassay for human prions.

Authors:  Tetsuyuki Kitamoto; Shirou Mohri; James W Ironside; Ichiro Miyoshi; Tomoyuki Tanaka; Noritoshi Kitamoto; Shigeyoshi Itohara; Noriyuki Kasai; Motoya Katsuki; Jun Higuchi; Tamaki Muramoto; Ryong-Woon Shin
Journal:  Biochem Biophys Res Commun       Date:  2002-06-07       Impact factor: 3.575

8.  A change in the conformation of prions accompanies the emergence of a new prion strain.

Authors:  David Peretz; R Anthony Williamson; Giuseppe Legname; Yoichi Matsunaga; Julie Vergara; Dennis R Burton; Stephen J DeArmond; Stanley B Prusiner; Michael R Scott
Journal:  Neuron       Date:  2002-06-13       Impact factor: 17.173

9.  Host genetic control of incubation periods of Creutzfeldt-Jakob disease in mice.

Authors:  S Mohri; J Tateishi
Journal:  J Gen Virol       Date:  1989-06       Impact factor: 3.891

10.  BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein.

Authors:  Emmanuel A Asante; Jacqueline M Linehan; Melanie Desbruslais; Susan Joiner; Ian Gowland; Andrew L Wood; Julie Welch; Andrew F Hill; Sarah E Lloyd; Jonathan D F Wadsworth; John Collinge
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

View more
  25 in total

1.  Huntington's disease: lessons from prion disorders.

Authors:  Melanie Alpaugh; Francesca Cicchetti
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

Review 2.  Molecular biology and pathology of prion strains in sporadic human prion diseases.

Authors:  Pierluigi Gambetti; Ignazio Cali; Silvio Notari; Qingzhong Kong; Wen-Quan Zou; Witold K Surewicz
Journal:  Acta Neuropathol       Date:  2010-11-07       Impact factor: 17.088

3.  Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties.

Authors:  Matthew T Bishop; Robert G Will; Jean C Manson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

4.  Co-occurrence of types 1 and 2 PrP(res) in sporadic Creutzfeldt-Jakob disease MM1.

Authors:  Atsushi Kobayashi; Kenta Mizukoshi; Yasushi Iwasaki; Hajime Miyata; Yasuji Yoshida; Tetsuyuki Kitamoto
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  Characterization of variant Creutzfeldt-Jakob disease prions in prion protein-humanized mice carrying distinct codon 129 genotypes.

Authors:  Atsuko Takeuchi; Atsushi Kobayashi; James W Ironside; Shirou Mohri; Tetsuyuki Kitamoto
Journal:  J Biol Chem       Date:  2013-06-21       Impact factor: 5.157

6.  Experimental verification of a traceback phenomenon in prion infection.

Authors:  Atsushi Kobayashi; Nobuyuki Sakuma; Yuichi Matsuura; Shirou Mohri; Adriano Aguzzi; Tetsuyuki Kitamoto
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

7.  Characterization of prion protein (PrP)-derived peptides that discriminate full-length PrPSc from PrPC.

Authors:  Anthony L Lau; Alice Y Yam; Melissa M D Michelitsch; Xuemei Wang; Carol Gao; Robert J Goodson; Robert Shimizu; Gulliver Timoteo; John Hall; Angelica Medina-Selby; Doris Coit; Colin McCoin; Bruce Phelps; Ping Wu; Celine Hu; David Chien; David Peretz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-29       Impact factor: 11.205

8.  Two different clinical phenotypes of Creutzfeldt-Jakob disease with a M232R substitution.

Authors:  Yusei Shiga; Katsuya Satoh; Tetsuyuki Kitamoto; Sigenori Kanno; Ichiro Nakashima; Shigeru Sato; Kazuo Fujihara; Hiroshi Takata; Keigo Nobukuni; Shigetoshi Kuroda; Hiroki Takano; Yoshitaka Umeda; Hidehiko Konno; Kunihiko Nagasato; Akira Satoh; Yoshito Matsuda; Mitsuru Hidaka; Hirokatsu Takahashi; Yasuteru Sano; Kang Kim; Takashi Konishi; Katsumi Doh-ura; Takeshi Sato; Kensuke Sasaki; Yoshikazu Nakamura; Masahito Yamada; Hidehiro Mizusawa; Yasuo Itoyama
Journal:  J Neurol       Date:  2007-11-02       Impact factor: 6.682

9.  Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles.

Authors:  Romolo Nonno; Michele A Di Bari; Franco Cardone; Gabriele Vaccari; Paola Fazzi; Giacomo Dell'Omo; Claudia Cartoni; Loredana Ingrosso; Aileen Boyle; Roberta Galeno; Marco Sbriccoli; Hans-Peter Lipp; Moira Bruce; Maurizio Pocchiari; Umberto Agrimi
Journal:  PLoS Pathog       Date:  2006-02-24       Impact factor: 6.823

10.  Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions.

Authors:  Déborah Tribouillard-Tanvier; Vincent Béringue; Nathalie Desban; Fabienne Gug; Stéphane Bach; Cécile Voisset; Hervé Galons; Hubert Laude; Didier Vilette; Marc Blondel
Journal:  PLoS One       Date:  2008-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.